Nusantara Vaccine By Terawan Cited Again In The International Journal

JAKARTA - The international medical journal Human Vaccines and Immunotherapeutics contains articles on the results of the Nusantara Vaccine clinical trial initiated by Lt. Gen. TNI (Ret.) Terawan Agus Putranto.

Terawan's team member, Andi, said the article, entitled "A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigenspecific cellular immune responses", published on August 26, 2022.

The article is the second article on the Nusantara Vaccine published in an international medical journal.

Previously, an article with the title "Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be Ex Vivo?" was published in the same journal on May 26, 2022.

"Doctor Terawan hopes that the article can be a reference for researchers," Andi said in a written statement, quoted from Antara, Monday, August 29.

In the latest article, it was stated that the purpose of the Nusantara Vaccine research was to determine the feasibility of preparing a personal dendritic cell vaccine for the spike protein of SARS-CoV-2 at the treatment point.

In addition, the study also aims to set short-term security after the single injection of a single subcutaneous vaccine, as well as determine the specific immune response of antigens after vaccination, and select the formulation you like for future trials.

The Nusantara vaccine is a dendritic cell-based COVID-19 vaccine. The process of making it is to take the patient's blood cells as a vaccine-making material.

Dendritic cells will be incubated and introduced with the recombinant SARS-COV-2 antigens. The incubation process takes 3 to 7 days.

Next, the vaccine will be injected back into the patient's body. The vaccine will trigger immune cells to form an immune system to reduce the risk of being infected with COVID-19.

"This can be a reference for the international medical world. Indonesia deserves to be proud," he said.

According to Andi, without the support of many parties, the development of the Nusantara Vaccine cannot reach what it is today.

"Doctor Terawan would like to thank all parties involved, including the support from President Joko Widodo and the Gatot Soebroto Army Hospital Team," he said.